treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: Mazujar Zulum
Country: Tanzania
Language: English (Spanish)
Genre: History
Published (Last): 24 December 2012
Pages: 314
PDF File Size: 4.43 Mb
ePub File Size: 1.24 Mb
ISBN: 290-5-26270-825-3
Downloads: 16963
Price: Free* [*Free Regsitration Required]
Uploader: Brakazahn

Cetuximab in the management of colorectal cancer

Together, these effects pl EGFR-mediated signaling leading to cell cycle arrest in G1, and pro-apoptotic processes Huang et al ; Kiyota et al ; Harding and Burtness Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

In a study of patients with head and neck cancer, patients received either a combination of radiation and cisplatin a cancer drugor ERBITUX in combination with radiation and ebitux.

Death occurred 27, 32, and 43 days after the last dose of Erbitux. No patient experienced grade 3 or 4 hypomagnesemia. Rontalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rontalizumab. Erbitux can cause interstitial pj disease ILD. There is no information regarding the presence of ERBITUX in human milk, the effects of the breastfed infant, or the effects on milk production.

Furthermore, several smaller trials in which cetuximab was added to first-line FOLFOX have produced promising results.

  EL AVARO PLAUTO PDF

Clazakizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Clazakizumab. Epidermal growth factor receptor as a target for chemotherapy. The risk or severity of adverse effects can be increased when Cetuximab is combined with IPH A total of patients were identified, all of whom received 50 mg of diphenhydramine before the first cetuximab dose and 25 mg before the second dose, consistent with institutional guidelines.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Tabalumab. Methallenestril Methallenestril may increase the thrombogenic activities of Cetuximab. Motavizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Motavizumab. Infusion reactions [see Warnings and Erbityx 5.

U Low affinity immunoglobulin gamma Fc region receptor II-a. Cetuximab is produced in mammalian murine myeloma cell culture.

TGA eBS – Product and Consumer Medicine Information

Bapineuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux administration [see Warnings and Precautions 5.

Indium In satumomab pendetide The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In satumomab pendetide.

The nature of the EGFR ligand as well as the coreceptor involved in dimerization determines which signaling pathways are activated and the final cellular response Yarden and Sliwkowski Please see additional Important Safety Information below. Trastuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab. Ustekinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ustekinumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Ravulizumab.

  LA LLUVIA DE FUEGO LEOPOLDO LUGONES PDF

Author information Copyright and License information Disclaimer.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Canakinumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Galiximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Ustekinumab.

Sacituzumab govitecan The risk or severity of adverse effects can be increased when Cetuximab is combined with Sacituzumab erbtux.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Human Varicella-Zoster Immune Globulin. Cetuximab also enhances radiosensitivity Huang et al Apolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Apolizumab.

Cetuximab – DrugBank

Aducanumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Aducanumab. Ascrinvacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ascrinvacumab.

Sarilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sarilumab. Preliminary results showed no major differences between the 2 schedules in terms of inhibition of EGFR signaling in skin.